Table 1.

Anti-HBV activity and cytotoxicity of compounds 10a-i, 17a-f, 5 and 22.

Compound	Anti-HBV activity (μM)		Cytotoxicity CC50 (μM)
	EC50	EC90	PBM	CEM	Vero	HepG2a
4	1.2 ± 0.6	6.3 ± 2.9	69.1	3.7	14.7	27.0
10a	5.6 ± 1.60	>10	57.9	70.3	89.0	>100
10b	0.09 ± 0.07	3.05 ± 1.83	>100	>100	68.1	>100
10c	0.47 ± 0.53	4.10 ± 2.42	>100	>100	31.2	>100
10d	3.8 ± 3.1	9.67 ± 0.47	>100	>100	>100	>100
10e	1.1 ± 1.5	4.62 ± 4.50	>100	>100	41.9	93.9
10f	0.56 ± 0.69	2.95 ± 2.51	≥100	37.9	80.1	>100
10g	0.08 ± 0.02	1.80 ± 1.23	>100	>100	13.4	>100
10h	0.41 ± 0.01	7.95 ± 0.07	>100	>100	62.4	>100
10i	5.16 ± 0.23	10.0 ± 0.03	>100	>100	91.4	>100
17a	0.004 ± 0.0001	0.06 ± 0.03	>100	14.6	>100	83.7
17b	0.005 ± 0.010	0.10 ± 0.04	≥ 100	24.7	≥ 100	95.4
17c	0.58 ± 0.08	5.64 ± 3.60	91.7	16.8	>100	89.9
17d	0.21 ± 0.74	3.44 ± 1.56	90.0	35.8	46.9	74.9
17e	0.16 ± 0.09	2.02 ± 1.68	>100	38.4	9.6	7.2
17f	0.01 ± 0.01	0.17 ± 0.23	>100	46.9	50.6	34.7
5 (GLP-26)	0.003 ± 0.002	0.014 ± 0.002	>100	>100	46.4	>100
22	0.006 ± 0.002	0.03 ± 0.003	>100	26.8	>100	83.9
GLS-4	0.08 ± 0.02	0.28 ± 0.06	28.4	68.7	17.7	>100
3TC	0.41 ± 0.36	1.65 ± 0.92	>100	>100	>100	>100
ETV	0.0006 ± 0.0003	0.011 ± 0.002	15.7	>100	>100	>100

ETV: Entecavir; 3TC: Lamivudine

^bAD38 cells are derived from HepG2 cells